<DOC>
	<DOCNO>NCT00945724</DOCNO>
	<brief_summary>This trial phase II non-comparative study aim determine feasibility toxicity R-CHOP regimen combination intrathecal liposomal cytarabine systemic intermediate-dose methotrexate follow loco-regional radiotherapy .</brief_summary>
	<brief_title>Safety Feasibility Study Combination State Art Chemoimmunotherapy , Intensive Central Nervous System Prophylaxis Scrotal Irradiation Treat Primary Diffuse Large B-cell Lymphoma Testis</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>1 . Patients primary testicular lymphoma diagnosis . Histological subtype include study Diffuse Large B Cell Lymphoma ( Attachment 2 : WHO classification lymphoma ) . 2 . Orchiectomy mandatory , enrolment patient study . 3 . Orchiectomy perform within 2 month study entry . 4 . Age 1880 5 . Untreated patient 6 . Ann Arbor Stage IE IIE . Bilateral testicular involvement presentation consider Stage IV . These patient may include study final Ann Arbor stage ( I II ) determine extent nodal disease . 7 . Bidimensionally measurable evaluable disease . Patients disease remove surgery eligible . 8 . Adequate haematological count : ANC &gt; 1.0 x 109/L PLTs count &gt; 75 x 109/L 9 . Cardiac ejection fraction ≥ 45 % MUGA scan echocardiography 10 . Non peripheral neuropathy active nonneoplastic CNS disease . 11 . No major lifethreatening illness may preclude chemotherapy 12 . Conjugated bilirubin ≤ 2 x ULN . 13 . Alkaline phosphatase transaminases ≤ 2 x ULN . 14 . Creatinine clearances ≥ 45 ml/min . 15 . HIV negativity 16 . HBV negativity patient HBVcAb + , HbsAg , HBs Ab+/ HBVDNA negative 17 . HCV negativity exception patient sign active chronic hepatitis histologically confirm 18 . Life expectancy &gt; 6 month . 19 . Performance status &lt; 2 accord ECOG scale . 20 . No psychiatric illness precludes understanding concept trial signing inform consent 21 . Written inform Consent 1 . Has know suspect hypersensitivity intolerance rituximab 2 . History clinically relevant liver renal insufficiency ; significant cardiac , vascular , pulmonary , gastrointestinal , endocrine , neurologic , rheumatologic , hematologic , psychiatric , metabolic disturbance 3 . Uncontrolled diabetes ( receive antidiabetic agent , subject must stable dose least 3 month first dose study drug ) 4 . Uncontrolled severe cardiovascular disease include myocardial infarction within 6 month enrollment , New York Heart Association ( NYHA ) Class III IV heart failure ( Attachment 5 , NYHA Classification Cardiac Disease ) , uncontrolled angina , clinically significant pericardial disease , cardiac amyloidosis 5 . History clinically relevant hypotension 6 . CNS involvement ( meningeal and/or brain involvement lymphoma ) 7 . Evolving malignancy within 3 year exception localize nonmelanomatous skin cancer 8 . HIV positivity 9 . HBV positivity exception patient HBVcAb + , HbsAg , HBs Ab+/ HBVDNA negative 10 . HCV positivity exception patient sign active chronic hepatitis histologically confirm 11 . Active opportunistic infection 12 . Receipt extensive radiation therapy , systemic chemotherapy , antineoplastic therapy 13 . Exposure Rituximab prior study entry 14 . Have receive experimental drug use experimental medical device within 4 week plan start treatment . Concurrent participation nontreatment study allow , interfere participation study . 15 . Any coexist medical psychological condition would preclude participation study compromise ability give inform consent</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>